You are here

FDA Denies Approval for Expanded Use of Xarelto (Rivaroxaban) in ACS

Second rejection for blood thinner (Mar. 4)

For the second time, the FDA has refused to approve the expanded use of the blood thinner Xarelto (rivaroxaban) to reduce the risk of heart attacks and stroke in patients with acute coronary syndrome (ACS), according to a Reuters report.

The drug was turned down in June for the same indication when the agency expressed concerns regarding missing trial data and the risk of bleeding.

In response, the drug’s developer, Johnson & Johnson, submitted data related to patients who had withdrawn from a pivotal clinical trial of Xarelto. The new information was also considered insufficient.

J&J said it is reviewing the new rejection letter.

Xarelto is approved for six other indications, including reducing the risk of blood clots in the legs and lungs of patients who have had hip- or knee-replacement surgery, and preventing strokes in patients with atrial fibrillation.

Source: Reuters; March 4, 2013.

Recent Headlines

Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers